Hyoscine Hydrobromide (BP/EP)
MHRA DMF MFD
17238-2-07323-0001

Alchem International with 75 years of experience in the phytochemical space has been diligently providing plant derived ingredients, active pharmaceutical ingredients and bulk drugs to all international significant geographies.

The success of the company's operations lie in its proprietary manufacturing processes, intensive research, willingness to combat new challenges, mesh with evolving technologies ,focussed expansion and credible response to international validations and inspections.

The production sites are WHO approved and US FDA & EU GMP inspected. The company has filed ASMF/DMFs in over 20 countries worldwide. Value additions through bio-technology, semi-synthesis and foot prints in the formulation space have happened in planned progression. Alchem's interest in skin care is a logical part of this dimensional growth.

Sheer Quality drives Alchem’s operations

Through perfect blend of science and nature, dedicated research, selection of finest botanical herbal extracts and focused technology, Alchem has successfully extracted the potent active molecules in the plant and offers it for pharmaceutical use to help various companies spread wellness.

Hyoscine hydrobromide
"For pharmaceutical use, Alchem offers Hyoscine hydrobromide with all its inherent benefits"

Scopolamine or hyoscine is a tropane alkaloid drug with muscarinic antagonist effects. It is among the secondary metabolites of plants from Solanaceae (nightshade) family of plants, such as henbane, jimson weed (Datura), angel's trumpets (Brugmansia), and corkwood (Duboisia). Hyoscine Hydrobromide is a semi-synthetic derivative of scopolamine that is derived from the purified extract of the Australian native Duboisia Bush. It is classified as an anticholinergic, antimuscarinic drug and its chief use is in the treatment of motion sickness and postoperative nausea and vomiting.

Hyoscine hydrobromide is a tertiary amine antimuscarinic agent, which competitively antagonizes acetylcholine. The main pharmacologic actions of hyoscine hydrobromide are a decrease in the production of salivary, bronchial and sweat gland secretions, dilated pupils (mydriasis), paralysis of accommodation (cycloplegia), a decrease in micturition, a decrease in gastrointestinal tone and gastric secretion, and bradycardia although transient tachycardia may be observed at higher doses.

Hyoscine hydrobromide is primarily used in various cases like prevention of nausea and vomiting associated with motion sickness, anesthetic premedication, urinary incontinence, symptomatic treatment of postencephalitic parkinsonism and paralysis agitans, as a substitute for atropine, in the accomplishment of cycloplegia and mydriasis for diagnostic procedures and for preoperative and postoperative states in treatment of iridocyclitis and finally to inhibit excessive motility and hypertonus of the GI tract in such conditions as irritable colon syndrome, mild dysentery, diverticulitis, pylorospasm, and cardiospasm.

The product addresses broad spectrum physiological concerns and has the band width and capabilities to meet expectations. Regular use should exhibit demonstrable results to inhibit various health related issues.